MRKR
NASDAQ
$1.28
Marker Therapeutics Inc (MRKR)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $7.87 (+514.84%)
Market Cap
$24M
Revenue 5Y CAGR
+53.28%
Free Cash Flow Yield
-33.63%
Beta (5Y)
1.16
Price Chart
Valuation
Market Cap$24M
P/S6.63
P/B1.75
Profitability
Total Revenue (TTM)$3.95M
Gross Profit (TTM)-$7.96M
EBITDA-$11M
Operating Margin-338.5%
EPS-$0.77
Financial Health
Free Cash Flow Yield-33.63%
Growth & Risk
EPS 5Y CAGR-32.88%
Revenue 5Y CAGR+53.28%
FCF 5Y CAGR-15.93%
Beta (5Y)1.16
Sharpe Ratio-0.12